Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Altimmune's stock, which was added to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, ...

The recent price decline of 12% in Altimmune, Inc.'s (NASDAQ:ALT) stock may have disappointed insiders who bought US$57.8k worth of shares at an average price of US$5.25 in the past 12 months.

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report sent to ...

The last time I wrote an article on Altimmune, Inc. (NASDAQ:ALT) it was in a Seeking Alpha article entitled "Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge." In this article ...

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:ALT), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...

Schroder Investment Management Group lessened its position in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 9.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm ...

In this article, we will see how Altimmune, Inc. (NASDAQ:ALT) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever ...

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%. Mar-25 6 calls and 3/28 weekly 5 puts are the most ...

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how Altimmune, Inc. (NASDAQ:ALT) compares to the other top short squeeze stocks ...